The molecular mechanisms underlying activation and/or inhibition of AMPK by UA are still unknown, but the experiments described above indicate that the modification of AMPK activity, including the use of XOR inhibitors, could be useful either to delay hepatic steatosis that could ultimately lead to cancer or to alleviate chemotherapeutic-induced toxicity. The gene discussed is XDH; the disease is cancer.